You have read all your free articles, to continue reading subscribe to read the rest of this content.
Orion upgrades the operations of its pharmaceutical plant in Turku by investing in a new cancer drug packaging line and by expanding its cream production department. The company is also building a new pure water system and district heating centre for the plant. The investments are due to the growAlready…
AstraZeneca will collaborate with ArcherDX, a genomic analysis company focused on precision oncology, to use personalized cancer monitoring to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer (NSCLC). ArcherDX’s personalized assay will be used in AstAlready a subscriber Login You have read all your free…
Oncopeptides has announced that the company has decided to withdraw Pepaxto (INN melphalan flufenamide) from the market in the US, following the phase 3 OCEAN study, which showed an overall survival in the ITT population with a HR of 1.104. The decision has been made after interactions and dialogAlready a…
Oncopeptides has announced that the Oncologic Drugs Advisory Committee (ODAC), of the FDA, has finalized the discussion on the benefit-risk profile of Pepaxto. A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient populatioAlready a subscriber Login You have read…
